Abstract
Pulmonary TB (TBP), caused by the bacillus Mycobacterium Tuberculosis (Mtb), is one of the most prevalent and deadly infectious diseases worldwide. With approximately a quarter of the global population affected, TB is one of the main causes of mortality within the spectrum of infectious diseases. Given this reality, there is an urgent need to explore and analyze new strategies that offer hope in the fight against this disease. The present article aims to offer an analytical review of emerging strategies in the treatment of TB. To achieve this objective, a comprehensive review methodology has been adopted, covering a wide range of recent bibliographic sources, including academic research and specialized literature. The purpose is to compile and synthesize the most significant and up-to-date contributions in the field, thus providing a clear and current overview of advances in the fight against TB.The article is structured in key sections covering the introduction to the basic concepts of TBS, the epidemiology and the interaction between Mtb and the host immune response, focusing on granuloma formation. In addition, pharmacodynamics and conventional treatments are discussed, along with a critical review on drug resistance. It concludes by highlighting the need for innovation and personalization in treatments to address drug resistance, offering a comprehensive view of the current challenges and solutions in TB management
Publisher
Salud, Ciencia y Tecnologia
Reference38 articles.
1. 1. Neri-vela R. La tuberculosis pulmonar. Aspectos históricos Lung tuberculosis . Historical aspects . Med Interna México [Internet]. 2023;39(1):114–26. Available from: https://d1wqtxts1xzle7.cloudfront.net/99056037/medintENE_FEB2023opinion1_La_tuberculosis_pulmonar._Aspectos_historicos-libre.pdf?1677211902=&response-content-disposition=inline%3B+filename%3DLa_tuberculosis_pulmonar_Aspectos_histor.pdf&Expires=1680912576&
2. 2. Sossen B, Richards AS, Heinsohn T, Frascella B, Balzarini F, Oradini-Alacreu A, et al. The natural history of untreated pulmonary tuberculosis in adults: a systematic review and meta-analysis. Lancet Respir Med [Internet]. 2023;11(4):367–79. Available from: https://journals.lww.com/ijebh/abstract/2014/03000/strategies_to_promote_adherence_to_treatment_by.2.aspx
3. 3. Akinnuwesi A, Egieyeh S, Cloete R. State-of-the-art strategies to prioritize Mycobacterium tuberculosis drug targets for drug discovery using a subtractive genomics approach. Front Drug Discov. 2023;3(September):1–8.
4. 4. Barberis I, Bragazzi NL, Galluzzo L, Martini M. The history of tuberculosis: From the first historical records to the isolation of Koch’s bacillus. J Prev Med Hyg [Internet]. 2017;58(1):E9–12. Available from: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5432783/pdf/2421-4248-58-E9.pdf
5. 5. Organización Mundial de la Salud. Tuberculosis [Internet]. Organización Mundial de la Salud. 2023. p. 1. Available from: https://www.who.int/es/news-room/fact-sheets/detail/tuberculosis